You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
The treatment of children with medicinal products is an important scientific area. It is recognized that many medicines that are used extensively in pediatric patients are either unlicensed or off-label. This textbook will help pediatric health professionals effectively treat children with the most appropriate medicine with minimal side effects.
The objective of this volume is to give an overview of the present state of the art of pediatric clinical pharmacology including developmental physiology, pediatric-specific pathology, special tools and methods for development of drugs for children (assessment of efficacy, toxicity, long-term safety etc.) as well as regulatory and ethical knowledge and skills. In the future, structural and educational changes have to lead back to a closer cooperation and interaction of pediatrics with (clinical) pharmacology and pharmacy.
The need for safe and effective use of medicines in children and WHO's initiative "Make Medicines Child Size" have boosted research and educational activities in the area of pediatric clinical drug research. This issue focuses on both general and specific aspects of neonatal and pediatric clinical pharmacology including ethics, pharmacogenomics, metabolomics, adverse drug reactions, pain medication, pulmonary hypertension and several other hot topics. The editors have been able to find outstanding authors for the different parts on neonatal and pediatric pharmacology.
Topic Editor Johannes N. van den Anker is the Chief Medical Officer at Reveragen Biopharma, as well as holding his positions at academic institutions. The other Topic Editor declares no competing interests with regard to the Research Topic subject.
Pharmacogenetics, Volume 83, the newest volume in the Advances in Pharmacology series, presents a variety of chapters and the best authors in the field, with this release highlighting regulatory perspectives, the implementation of pharmacogenetics in everyday clinical setting, imaging in pharmacogenetics, pharmacoepidemiology in pharmacogenetics, epigenetics and micro RNA in pharmacogenetics, ethnicity in pharmacogenetics, pediatric pharmacogenetics, pharmacogenetics and adverse drug reactions, and cytochrome P450 pharmacogenetics amongst other important topics. This series presents an essential resource for pharmacologists, immunologists, and biochemists alike. - Includes the authority and expertise of leading contributors in pharmacology as sourced from an international board of authors - Presents the latest release in the Advances in Pharmacology series
Covers the general principles of pediatric pharmacology from a clinical perspective. Over 80 distinguished authorities discuss drugs and pregnancy, with special emphasis on maternal-fetal medicine, drugs and the infant, child, and adolescent, as well as specific drugs and adverse drug effects.
The study of interactions between genes and environmental exposures ha s expanded considerably in recent years. Highly penetrant genes that a re involved in familial cancer have been identified, but are likely to account for a relatively small proportion of total cancers. Other pre disposing genes have low penetrance, resulting in a moderate increase in the risk of specific cancers, but are widespread in the general pop ulation. This is the case for so-called metabolic polymorphisms. Scien tific interest in metabolic polymorphisms is based on the possibility of identifying subgroups of the population which are at elevated risk of developing environmentally-induced cancer. However, such studies ra ise a series of problems that are methodological - related to the stud y design and analysis - and ethical - related to the practical use tha t can be made of genetic information. This volume deals thoroughly wit h such problems.